| 2025-11-14 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.42美元,归母净利润-3517万美元,同比去年增长-517.05%
|
| 2025-11-13 |
详情>>
股本变动：
变动后总股本7503.43万股
变动原因 ▼▲
- 原因：
- Common Stock offered 15,152,485 shares by the company
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.21美元,归母净利润-1771.1万美元,同比去年增长74.16%
|
| 2025-08-14 |
详情>>
业绩披露：
2024年年报每股收益-0.66美元,归母净利润-3618.4万美元,同比去年增长68.95%
|
| 2025-08-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.08美元,归母净利润-649.5万美元,同比去年增长72.51%
|
| 2025-04-29 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.To elect Keith A. Katkin, Allan D. Kirk, M.D., Ph.D., FACS. and John S. McBride as Class II directors to serve until Eledon’s 2028 annual meeting of stockholders and until their respective successors have been duly elected and qualified;
2.To approve an amendment to the Company’s Restated Certificate of Incorporation, (as amended, the “Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock, par value $0.001 per share, from 200,000,000 to 300,000,000;
3.To approve an amendment to the Certificate of Incorporation, to provide for exculpation of certain officers;
4.To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.13美元,归母净利润843.30万美元,同比去年增长127.47%
|
| 2024-08-19 |
详情>>
业绩披露：
2023年年报每股收益-4.73美元,归母净利润-1.17亿美元,同比去年增长-32.48%
|
| 2024-08-19 |
详情>>
业绩披露：
2024年一季报每股收益-0.79美元,归母净利润-2363.1万美元,同比去年增长-119.37%
|
| 2024-08-19 |
详情>>
业绩披露：
2024年中报每股收益-1.9美元,归母净利润-6853.8万美元,同比去年增长-236.78%
|
| 2024-05-30 |
股东大会：
将于2024-07-10召开股东大会
会议内容 ▼▲
- 1.Election of Steven Perrin, Ph.D. and June Lee, M.D. as Class I directors to serve until Eledon’s 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.
2.Approval of an amendment to the 2020 Incentive Plan to increase the aggregate number of shares available for issuance thereunder by 3,500,000 shares.
3.Ratification of the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the year ending December 31, 2024.
4.Any other business properly brought before the meeting or any postponement or adjournment thereof.
|
| 2024-05-09 |
详情>>
内部人交易：
BVF PARTNERS L P/IL共交易3笔
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.35美元,归母净利润-3070万美元,同比去年增长-3.78%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-1.06美元,归母净利润-2035.1万美元,同比去年增长-6.49%
|
| 2023-05-11 |
财报披露：
美东时间 2023-05-11 盘后发布财报
|
| 2023-05-01 |
股东大会：
将于2023-06-21召开股东大会
会议内容 ▼▲
- 1.Election of David-Alexandre C. Gros, M.D. and Jan Hillson, M.D. as Class III directors to serve until Eledon’s 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified.
2.To increase the aggregate number of shares available for issuance under the 2020 Incentive Plan by 9,600,000 shares.
3.To approve, on an advisory basis, the compensation of our named executive officers.
4.To ratify the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the year ending December 31, 2023.
5.To conduct any other business properly brought before the meeting or any postponement or adjournment thereof.
|
| 2022-05-25 |
复牌提示：
2022-05-24 15:51:16 停牌，复牌日期 2022-05-24 16:00:00
|
| 2022-04-28 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.Election of Keith A. Katkin and John S. McBride as Class II directors to serve until Eledon’s 2025 annual meeting of stockholders and until their respective successors have been duly elected and qualified.
2.To ratify the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the year ending December 31, 2022.
3.To conduct any other business properly brought before the meeting or any postponement or adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.To elect the three Class I directors named in the proxy statement, each to serve for a three year term expiring at the 2024 annual meeting of stockholders and until their successor has been duly elected and qualified;
2.To ratify the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2020-11-20 |
股东大会：
将于2020-12-18召开股东大会
会议内容 ▼▲
- 1.Novus will ask its stockholders to approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of the Company’s Common Stock, upon conversion of the Company’s Series X1 Preferred Stock issued in September 2020;
2.Novus will ask its stockholders to approve a new Novus Therapeutics, Inc. 2020 Long Term Incentive Plan, which we refer to below as the “2020 Incentive Plan.” The Board of Directors currently intends that upon approval of the 2020 Incentive Plan, awards will no longer be made under the Novus Therapeutics, Inc. 2014 Stock Incentive Plan;
3.Novus will ask its stockholders to ratify an amendment to our bylaws to allow for participation in stockholder meetings by means of virtual meeting technology;
4.Novus will ask its stockholders to approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1, 2 and/or 3.
|
| 2020-10-05 |
详情>>
拆分方案：
每18.0000合并分成1.0000股
|
| 2020-03-31 |
股东大会：
将于2020-05-12召开股东大会
会议内容 ▼▲
- 1.To elect the two Class III directors named in the proxy statement, each to serve for a three year term expiring at the 2023 annual meeting of stockholders and until his successor has been duly elected and qualified;
2.To ratify the appointment of KMJ Corbin & Company LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020
3.To approve and adopt an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split (the “Reverse Stock Split Amendment”) of the Company’s common stock at a ratio ranging from 1 share-for-10 shares up to a ratio of 1 share-for-30 shares, which ratio will be selected by the Company’s Board of Directors and set forth in a public announcement;
4.To conduct an advisory (non-binding) vote to approve the Company’s executive compensation;
5.To conduct an advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation;
6.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2019-05-15 |
股东大会：
将于2019-07-11召开股东大会
会议内容 ▼▲
- 1.The election of the two Class II directors named in the proxy statement, each to serve for a three year term expiring at the 2022 annual meeting of stockholders and until his successor has been duly elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-13召开股东大会
会议内容 ▼▲
- 1.The election of two Class I directors nominated by our board of directors, each to serve for a three year term expiring at the 2021 annual meeting of stockholders and until her/his successor has been duly elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2017-08-18 |
股东大会：
将于2017-09-28召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2020 annual meeting of stockholders and until his successor has been duly elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2017-05-10 |
详情>>
拆分方案：
每9.0000合并分成1.0000股
|
| 2017-04-07 |
股东大会：
将于2017-05-09召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of shares of common stock of Tokai, par value $0.001 per share (“Tokai common stock”), pursuant to the terms of the Share Purchase Agreement, as amended and restated on March 2, 2017 (the “Share Purchase Agreement”), by and among Tokai, Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (“Otic”), and the shareholders of Otic named therein (each a “Seller” and collectively, the “Sellers”) (the “Otic Transaction”) (such proposal, the “Share Issuance Proposal”). A copy of the Share Purchase Agreement is attached as Annex A to the accompanying proxy statement;
2.To approve the issuance of shares of Tokai common stock pursuant to the terms of the Stock Purchase Agreement, dated as of January 31, 2017 (the “Tokai Stock Purchase Agreement”), by and among Tokai and the purchasers set forth therein (the “Purchasers”) (the “Equity Financing”) (such proposal, the “Equity Financing Proposal”). A copy of the Tokai Stock Purchase Agreement is attached as Annex B to the accompanying proxy statement;
3.To approve and adopt an amendment to Tokai’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of Tokai common stock, at a ratio ranging from 1:1 to 1:10, as determined by the Tokai board of directors and agreed to by Otic, as more fully set forth in the accompanying proxy statement (the “Reverse Stock Split Proposal”). A copy of the form of amendment to Tokai’s Amended and Restated Certificate of Incorporation to effect the reverse stock split is attached as Annex C to the accompanying proxy statement;
4.To adjourn the special meeting to solicit additional votes to approve the Share Issuance Proposal, the Equity Financing Proposal or the Reverse Stock Split Proposal, if necessary or appropriate (the “Adjournment Proposal”);
5.Any other business that may properly come before the special meeting and any adjournments or postponements thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-15召开股东大会
会议内容 ▼▲
- 1. The election of two Class II directors nominated by our board of directors, each to serve for a three-year term expiring at the 2019 annual meeting of stockholders and until his successor has been duly elected and qualified;
2. The ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|